151 related articles for article (PubMed ID: 29728736)
1. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
2. A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Scapinello G; Riva M; Branca A; Pizzi M; Bonaldi L; Martines A; Manni S; Visentin A; Trentin L; Semenzato G; Gurrieri C; Piazza F
Ann Hematol; 2020 Nov; 99(11):2715-2717. PubMed ID: 32671454
[No Abstract] [Full Text] [Related]
3. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
4. The t(9;14)(p13;q32) is a recurrent but rare abnormality in splenic marginal zone lymphoma.
Kelly RJ; O'connor SJ; Barrans SL; Johnson RJ; Owen RG
Leuk Lymphoma; 2007 Aug; 48(8):1636-7. PubMed ID: 17701598
[No Abstract] [Full Text] [Related]
5. t(14;18)(q32;q21)-bearing pleural MALT lymphoma with IgM paraproteinemia: value of detection of specific cytogenetic abnormalities in the differential diagnosis of MALT lymphoma and lymphoplasmacytic lymphoma.
Gomyo H; Kajimoto K; Maeda A; Mizuno I; Funada Y; Koizumi T; Fukui E; Hanioka K; Ogura M; Murayama T
Hematology; 2007 Aug; 12(4):315-8. PubMed ID: 17654058
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
7. t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia.
Liu D; Shimonov J; Primanneni S; Lai Y; Ahmed T; Seiter K
Mol Cancer; 2007 Jun; 6():35. PubMed ID: 17547754
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous presence of t(2;8)(p12;q24) and t(14;18)(q32;q21) in a B-cell lymphoproliferative disorder with features suggestive of an aggressive variant of splenic marginal-zone lymphoma.
Batanian JR; Dunphy CH; Richart JM; Petruska PJ; Perkins SL
Cancer Genet Cytogenet; 2000 Jul; 120(2):136-40. PubMed ID: 10942804
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
10. Burkitt lymphoma following splenic marginal zone lymphoma. evidence for two independent B-cell clones.
Heintel D; Streubel B; Welzel N; Le T; Schwarzinger I; Haas OA; Simonitsch I; Lechner K; Jaeger U
Cancer Genet Cytogenet; 2003 Feb; 141(1):86-8. PubMed ID: 12581905
[TBL] [Abstract][Full Text] [Related]
11. Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma.
Baró C; Salido M; Domingo A; Granada I; Colomo L; Serrano S; Solé F
Haematologica; 2006 Sep; 91(9):1289-91. PubMed ID: 16956840
[TBL] [Abstract][Full Text] [Related]
12. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases.
Baseggio L; Traverse-Glehen A; Petinataud F; Callet-Bauchu E; Berger F; Ffrench M; Couris CM; Thieblemont C; Morel D; Coiffier B; Salles G; Felman P
Haematologica; 2010 Apr; 95(4):604-12. PubMed ID: 20015887
[TBL] [Abstract][Full Text] [Related]
13. Splenic marginal zone lymphoma with increased prolymphocytes.
Cai J; Qing X
Blood; 2021 Jun; 137(22):3150. PubMed ID: 34081119
[No Abstract] [Full Text] [Related]
14. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
15. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.
Streubel B; Vinatzer U; Lamprecht A; Raderer M; Chott A
Leukemia; 2005 Apr; 19(4):652-8. PubMed ID: 15703784
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma carrying both t(3 ; 7)(q27 ; p12) and t(8 ; 14)(q24 ; q32).
Katsura Y; Ohta I; Yoshida C; Ohtani H; Komeno T
Intern Med; 2011; 50(8):905-8. PubMed ID: 21498940
[TBL] [Abstract][Full Text] [Related]
17. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
18. IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Ville S; Kandel C; Delaunay J; Cantarovich D
Nephrology (Carlton); 2020 May; 25(5):429-430. PubMed ID: 31726478
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Cencini E; Fabbri A; Schiattone L; Bocchia M
Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
[No Abstract] [Full Text] [Related]
20. Double-hit lymphoma with t(8;14)(q24;q32) and t(12;14)(q24;q32) chromosomal translocations.
Yamazaki T; Ohno H
Intern Med; 2011; 50(21):2659-62. PubMed ID: 22041376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
